Nous utilisons des cookies pour nous assurer que nous vous offrons la meilleure expérience possible sur notre site web.
Yverdon-les-Bains, Switzerland – Symbios, the world leader in individualized orthopedic implants, is pleased to announce the relocation of its headquarters and production facility to a new industrial site in Yverdon-les-Bains.
This new site, on which construction began in 2020 and was completed at the end of 2023, will become Symbios' headquarters and sole manufacturing site, and will enable the group to increase its production capacity and accelerate its growth in the coming years, particularly through the opening up of new strategic markets such as the United States of America.
“We are pleased to formalize the transfer of our headquarters and industrial activities to this new site while remaining in Yverdon-les-Bains. This marks an important milestone for the company and all its employees,” said Florent Plé, President & CEO of Symbios.
Located less than a kilometer from the old factory, this new site has a scalable surface area of more than 12,000 m2, a state-of-the-art industrial infrastructure and the latest automation technologies to increase Symbios' production capacity fourfold while guaranteeing compliance with ever more demanding quality standards. A pioneer in its field since 1989, Symbios continues to innovate with this new state-of-the-art production site, which now sets the global standard for the production of individualized orthopedic implants.
“This new factory was built specifically to enable Symbios to industrialize the production of individualized implants at a level never achieved before, in order to meet the rapidly increasing demand worldwide for individualized medicine,” added Florent Plé. “We are proud to continue developing our activities in the Canton of Vaud, where the company was founded 35 years ago, and to contribute to promoting Swiss excellence in medical technology throughout the world.”